Sanctuary Advisors LLC Buys Shares of 27,347 Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Sanctuary Advisors bought a new stake of 27,347 shares in Arrowhead Pharmaceuticals in Q4, valued at about $1.82 million per the latest 13F filing.
• Arrowhead's most recent quarter showed a $0.22 EPS (missing the $0.60 estimate) but revenue of $264.0M, an outsized year-over-year increase of roughly 10,461%.
• Institutional investors own roughly 62.6% of ARWR, with large position increases from funds such as Arrowstreet, and analysts carry a consensus "Moderate Buy" rating with an average target of $84.20.

Sanctuary Advisors LLC bought a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 27,347 shares of the biotechnology company's stock, valued at approximately $1,816,000.

Several other institutional investors have also recently bought and sold shares of ARWR. Arrowstreet Capital Limited Partnership lifted its stake in Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company's stock valued at $71,797,000 after acquiring an additional 2,017,489 shares in the last quarter. Deerfield Management Company L.P. bought a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $34,249,000. Balyasny Asset Management L.P. bought a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $27,349,000. Baker BROS. Advisors LP lifted its stake in Arrowhead Pharmaceuticals by 77.9% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,670,762 shares of the biotechnology company's stock valued at $57,625,000 after acquiring an additional 731,588 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its stake in Arrowhead Pharmaceuticals by 133.3% in the 3rd quarter. Fisher Asset Management LLC now owns 1,053,794 shares of the biotechnology company's stock valued at $36,345,000 after acquiring an additional 602,139 shares in the last quarter. Institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $74.81 on Monday. The firm has a market capitalization of $10.48 billion, a price-to-earnings ratio of 48.90 and a beta of 1.28. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $12.44 and a twelve month high of $76.76. The stock's 50 day moving average price is $63.47 and its two-hundred day moving average price is $59.52. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.38). The company had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The firm's revenue for the quarter was up 10461.3% compared to the same quarter last year. During the same period last year, the firm earned ($1.39) EPS. Equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on ARWR shares. Weiss Ratings upgraded Arrowhead Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Friday, February 6th. The Goldman Sachs Group boosted their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a "neutral" rating in a research note on Wednesday, January 7th. HC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, March 25th. Chardan Capital boosted their target price on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a "buy" rating in a research note on Wednesday, January 7th. Finally, B. Riley Financial boosted their target price on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a "buy" rating in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $84.20.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CFO Daniel Joseph Apel sold 13,095 shares of the business's stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer owned 162,905 shares of the company's stock, valued at $11,623,271.75. The trade was a 7.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the transaction, the insider directly owned 226,958 shares in the company, valued at $17,021,850. This trade represents a 4.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 33,095 shares of company stock worth $2,326,228 in the last ninety days. Insiders own 3.60% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.